Patients with high tumour PME‐1 expression had significantly shorter time to secondary therapies after primary treatment (i.e., relapse‐free survival; Fig. 1B), indicative of clinical relevance of PME‐1 in human PCa. Here, PPME1 is linked to posterior cortical atrophy.